Cladribine - MS Research Australia

Cladribine

Cladribine

Administration Route: Oral
Injection site:  N/A
Frequency: Two treatment courses, twelve months apart
TGA approval date: 1/09/2010
PBS listed: No
Mechanism of action As a purine analog, it is a synthetic chemotherapy agent that targets lymphocytes and selectively suppresses the immune system, its exact mechanism of action in MS is not clear.
%reduction in relapse rate, impact of progression 64% RRR in annual relapse rate
Pregnancy Category D
Safe in Pregnancy Spected to cause or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage.
Breastfeeding (information predominatly from  LACTMED database) Because there is no published experience with cladribine during breastfeeding, it should be avoided during breastfeeding, especially while nursing a newborn or preterm infant.
Monitoring requirements Careful hematologic monitoring is recommended
Potential side effects (not a comprehensive list) Reduction in white blood cells, fatigue, nausea, rash, headache
Manufacturer Merck Serono
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search